Recruiting
Phase 2
Phase 3

BHV-7000

Sponsor:

Biohaven Therapeutics Ltd.

Code:

NCT06132893

Conditions

Focal Epilepsy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BHV-7000

BHV-7000

Placebo

BHV-7000

Placebo

Study Details

Brief summary:

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Conditions

Focal Epilepsy

Study ID

NCT06132893

Start date

Mar 14, 2024

Status verified date

Aug, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

1. Male and Female participants 18 to 75 years of age at time of consent.
2. Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.

a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures iii. Focal to bilateral tonic-clonic seizures
3. Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.
4. Ability to keep accurate seizure diaries
5. Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total

Key Exclusion Criteria:

1. History of status epilepticus (convulsive status epilepticus for > 5 minutes or focal status epilepticus with impaired consciousness for > 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure.
2. History of repetitive/cluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase.
3. Resection neurosurgery for seizures <4 months prior to the screening visit.
4. Radiosurgery performed <2 years prior to the screening visit.
5. Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms.
6. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator

Study Design

Enrollment

390 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: BHV-7000 25 mg Part A

experimental: BHV-7000 50 mg Part A

placebo comparator: Placebo Part A

experimental: BHV-7000 75 mg Part B

placebo comparator: Placebo Part B

Interventions

BHV-7000

BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily

BHV-7000

BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily

Placebo

Matching placebo taken once daily

BHV-7000

BHV-7000 75 mg. Participants willtake blinded investigational product(IP) once daily

Placebo

Matching placebo taken once daily

Primary outcome measure

  • Part B: Change from Baseline in 28-day average seizure frequency [ Time Frame: Baseline, Week 8 to Week 20 of Part B ]
  • Part A: Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs [ Time Frame: Week 8 to Week 20 of Part A ]
  • Part A: Number of Participants With Clinically Significant Laboratory Abnormalities [ Time Frame: Week 8 to Week 20 of Part A ]

Central Contacts and Locations

Central contacts

Locations

Barrow Neurological Institute

Recruiting

Phoenix, Arizona, United States, 85013

Contacts

Center for Neurosciences

Recruiting

Tucson, Arizona, United States, 85718

Contacts

Clinical Trials, Inc.

Recruiting

Little Rock, Arkansas, United States, 72205

Contacts

University of California San Diego

Recruiting

La Jolla, California, United States, 92041

Contacts

Jonathan Rodriguez

jor010@health.ucsd.edu

University of California, Los Angeles

Recruiting

Los Angeles, California, United States, 90095

Contacts

Stanford Health Care

Recruiting

Palo Alto, California, United States, 94304

Contacts

University of Colorado Anschultz Medical Campus

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Yale School of Medicine - Yale-New Haven Hospital

Recruiting

New Haven, Connecticut, United States, 06519

Nova Clinical Research, LLC

Recruiting

Bradenton, Florida, United States, 34209

Contacts

University of Florida (Jacksonville)

Recruiting

Jacksonville, Florida, United States, 32209

Contacts

University of Miami

Recruiting

Miami, Florida, United States, 33136

Contacts

Medsol Clinical Research Center

Recruiting

Port Charlotte, Florida, United States, 33952

Contacts

Santos Research Center

Recruiting

Tampa, Florida, United States, 33615

Contacts

Encore Medical Research of Weston LLC.

Recruiting

Weston, Florida, United States, 33331

Contacts

Augusta University

Recruiting

Augusta, Georgia, United States, 30912

Contacts

Hawaii Pacific Neuroscience

Recruiting

Honolulu, Hawaii, United States, 96817

Contacts

Consultants in Epilepsy & Neurology, PLLC

Recruiting

Boise, Idaho, United States, 83702

Contacts

Northwestern University

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Bluegrass Epilepsy Research

Recruiting

Lexington, Kentucky, United States, 40504

Contacts

MAESC

Recruiting

Bethesda, Maryland, United States, 20817

Contacts

Minnesota Epilepsy Group, P.A.

Recruiting

Roseville, Minnesota, United States, 55113

Contacts

Washington University School of Medicine

Recruiting

St Louis, Missouri, United States, 63110

Contacts

NEREG

Recruiting

Hackensack, New Jersey, United States, 07601

Contacts

Inst of Neurology

Recruiting

Livingston, New Jersey, United States, 07039

Contacts

Dent Neurosciences Research Center

Recruiting

Amherst, New York, United States, 14226

Contacts

BCHP

Recruiting

Hawthorne, New York, United States, 10532

Contacts

Northwell Health

Recruiting

New York, New York, United States, 10021

Contacts

Stony Brook Medicine

Recruiting

Stony Brook, New York, United States, 11794

Contacts

Five Towns Neuroscience Research

Recruiting

Woodmere, New York, United States, 11598

Contacts

Wake Forest Baptist

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

NeuroScience Research Center

Recruiting

Canton, Ohio, United States, 44718

Contacts

University of Cincinnati

Recruiting

Cincinnati, Ohio, United States, 45267

Contacts

OSU

Recruiting

Columbus, Ohio, United States, 43214

Contacts

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Thomas Jefferson University

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

UPMC

Recruiting

Pittsburgh, Pennsylvania, United States, 15213

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Neurology Consultants of Dallas, PA

Recruiting

Dallas, Texas, United States, 75243

Contacts

UT Health San Antonio

Recruiting

San Antonio, Texas, United States, 78229

Contacts

Road Runner Research, Ltd

Recruiting

San Antonio, Texas, United States, 78249

Contacts

University of Utah

Recruiting

Salt Lake City, Utah, United States, 84132

Contacts

University of Virginia

Recruiting

Charlottesville, Virginia, United States, 22903

Contacts

Henrico Doctors Neurology Associates, LLC

Recruiting

Richmond, Virginia, United States, 23235

Contacts

Carilion Clinic

Recruiting

Roanoke, Virginia, United States, 24011

Contacts

More Information

Sponsor

Biohaven Therapeutics Ltd.

Last update posted

Aug 24, 2026

Last verified

Aug, 2026

Keywords

  • Focal Epilepsy
  • Epilepsy
  • Seizure
  • Refractory Epilepsy
  • Partial Epilepsy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Biohaven Therapeutics Ltd. on 2026-08-24.